{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:17:07Z","timestamp":1789078627657,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40262-025-01533-0","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T14:51:49Z","timestamp":1751295109000},"page":"1379-1394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Population Pharmacokinetic Model and Dosing Algorithm to Guide the Tacrolimus Starting and Follow-Up Dose in Living and Deceased Donor Kidney Transplant Recipients"],"prefix":"10.1007","volume":"64","author":[{"given":"Marith I.","family":"Francke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan D. T.","family":"Sassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lloberas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Colom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Elens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Moudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko P. J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C. M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"2","key":"1533_CR1","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000644","volume":"3","author":"LM Andrews","year":"2017","unstructured":"Andrews LM, de Winter BC, Tang JT, Shuker N, Bouamar R, van Schaik RH, et al. Overweight kidney transplant recipients are at risk of being overdosed following standard bodyweight-based tacrolimus starting dose. Transplant Direct. 2017;3(2): e129.","journal-title":"Transplant Direct."},{"issue":"6","key":"1533_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/j.1365-2125.2011.04039.x","volume":"72","author":"C Passey","year":"2011","unstructured":"Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72(6):948\u201357.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1533_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","volume":"31","author":"RR Press","year":"2009","unstructured":"Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31(2):187\u201397.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"1533_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1517\/17425255.2015.1033397","volume":"11","author":"LM Andrews","year":"2015","unstructured":"Andrews LM, Riva N, de Winter BC, Hesselink DA, de Wildt SN, Cransberg K, van Gelder T. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opin Drug Metab Toxicol. 2015;11(6):921\u201336.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"1533_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","volume":"56","author":"F Andreu","year":"2017","unstructured":"Andreu F, Colom H, Elens L, van Gelder T, van Schaik RHN, Hesselink DA, et al. A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach. Clin Pharmacokinet. 2017;56(8):963\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1533_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E Storset","year":"2014","unstructured":"Storset E, Holford N, Midtvedt K, Bremer S, Bergan S, Asberg A. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol. 2014;70(1):65\u201377.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1533_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00228-012-1296-4","volume":"69","author":"N Han","year":"2013","unstructured":"Han N, Yun HY, Hong JY, Kim IW, Ji E, Hong SH, et al. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol. 2013;69(1):53\u201363.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1533_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","volume":"36","author":"TK Bergmann","year":"2014","unstructured":"Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 2014;36(1):62\u201370.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1533_CR9","doi-asserted-by":"publisher","first-page":"E272","DOI":"10.1111\/ctr.12101","volume":"27","author":"SY Chen","year":"2013","unstructured":"Chen SY, Li JL, Meng FH, Wang XD, Liu T, Li J, et al. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism\u2014a prospective, randomized, controlled study. Clin Transplant. 2013;27(3):E272\u201381.","journal-title":"Clin Transplant"},{"key":"1533_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejps.2013.10.008","volume":"52","author":"B Golubovic","year":"2014","unstructured":"Golubovic B, Vucicevic K, Radivojevic D, Kovacevic SV, Prostran M, Miljkovic B. Total plasma protein effect on tacrolimus elimination in kidney transplant patients\u2014population pharmacokinetic approach. Eur J Pharm Sci. 2014;52:34\u201340.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"1533_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/FPC.0b013e32835fcbb6","volume":"23","author":"XC Zuo","year":"2013","unstructured":"Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013;23(5):251\u201361.","journal-title":"Pharmacogenet Genomics"},{"issue":"12","key":"1533_CR12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/tri.12194","volume":"26","author":"A Asberg","year":"2013","unstructured":"Asberg A, Midtvedt K, van Guilder M, Storset E, Bremer S, Bergan S, et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int. 2013;26(12):1198\u2013207.","journal-title":"Transpl Int"},{"issue":"6","key":"1533_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1365-2125.2007.02888.x","volume":"64","author":"M Antignac","year":"2007","unstructured":"Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007;64(6):750\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1533_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/clpt.2009.210","volume":"86","author":"W Zhao","year":"2009","unstructured":"Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86(6):609\u201318.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1533_CR15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40262-017-0567-8","volume":"57","author":"LM Andrews","year":"2018","unstructured":"Andrews LM, Hesselink DA, van Gelder T, Koch BCP, Cornelissen EAM, Bruggemann RJM, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation. Clin Pharmacokinet. 2018;57(4):475\u201389.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1533_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/bcp.13838","volume":"85","author":"LM Andrews","year":"2019","unstructured":"Andrews LM, Hesselink DA, van Schaik RHN, van Gelder T, de Fijter JW, Lloberas N, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2019;85(3):601\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1533_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/jcpt.12523","volume":"42","author":"HJ Zhang","year":"2017","unstructured":"Zhang HJ, Li DY, Zhu HJ, Fang Y, Liu TS. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther. 2017;42(4):425\u201332.","journal-title":"J Clin Pharm Ther"},{"key":"1533_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fphar.2017.00358","volume":"8","author":"JB Woillard","year":"2017","unstructured":"Woillard JB, Mourad M, Neely M, Capron A, van Schaik RH, van Gelder T, et al. Tacrolimus updated guidelines through popPK modeling: how to benefit more from CYP3A pre-emptive genotyping prior to kidney transplantation. Front Pharmacol. 2017;8:358.","journal-title":"Front Pharmacol"},{"key":"1533_CR19","doi-asserted-by":"crossref","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharmacokinet. 2020;59(11):1357\u201392.","DOI":"10.1007\/s40262-020-00922-x"},{"issue":"3","key":"1533_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"key":"1533_CR21","doi-asserted-by":"crossref","unstructured":"Koomen JV, Knobbe TJ, Zijp TR, Kremer D, Gan CT, Verschuuren EAM, et al. A Joint pharmacokinetic model for the simultaneous description of plasma and whole blood tacrolimus concentrations in kidney and lung transplant recipients. Clin Pharmacokinet. 2023;62(8):1117\u201328.","DOI":"10.1007\/s40262-023-01259-x"},{"key":"1533_CR22","doi-asserted-by":"crossref","unstructured":"Lloberas N, Griny\u00f3 JM, Colom H, Vidal-Alabr\u00f3 A, Fontova P, Rigo R, et al. A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction. Kidney Int. 2023;104(4):840\u201350.","DOI":"10.1016\/j.kint.2023.06.021"},{"key":"1533_CR23","doi-asserted-by":"crossref","unstructured":"Schagen MR, Volarevic H, Francke MI, Sassen SDT, Reinders MEJ, Hesselink DA, de Winter BCM. Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs. Expert Opin Drug Metab Toxicol. 2023;19(7):429\u201345.","DOI":"10.1080\/17425255.2023.2250251"},{"issue":"8","key":"1533_CR24","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/jcph.1823","volume":"61","author":"M Al-Kofahi","year":"2021","unstructured":"Al-Kofahi M, Oetting WS, Schladt DP, Remmel RP, Guan W, Wu B, et al. Precision dosing for tacrolimus using genotypes and clinical factors in kidney transplant recipients of European ancestry. J Clin Pharmacol. 2021;61(8):1035\u201344.","journal-title":"J Clin Pharmacol"},{"key":"1533_CR25","doi-asserted-by":"crossref","unstructured":"Francke MI, Andrews LM, Le HL, van de Wetering J, Clahsen-van Groningen MC, van Gelder T, et al. Avoiding tacrolimus underexposure and overexposure with a dosing algorithm for renal transplant recipients: a single arm prospective intervention trial. Clin Pharmacol Ther. 2021;110(1):169\u201378.","DOI":"10.1002\/cpt.2163"},{"issue":"7","key":"1533_CR26","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1111\/ajt.13691","volume":"16","author":"N Shuker","year":"2016","unstructured":"Shuker N, Bouamar R, van Schaik RH, Clahsen-van Groningen MC, Damman J, Baan CC, et al. A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2016;16(7):2085\u201396.","journal-title":"Am J Transplant"},{"issue":"Suppl 2","key":"1533_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/ajt.16502","volume":"21","author":"A Hart","year":"2021","unstructured":"Hart A, Lentine KL, Smith JM, Miller JM, Skeans MA, Prentice M, et al. OPTN\/SRTR 2019 annual data report: kidney. Am J Transplant. 2021;21(Suppl 2):21\u2013137.","journal-title":"Am J Transplant"},{"key":"1533_CR28","unstructured":"Eurotransplant. Annual report 2023. https:\/\/www.eurotransplant.org\/2024\/06\/11\/eurotransplant-publishes-annual-report-2023\/Eurotransplant publishes Annual Report 2023 - EurotransplantETP_AR2023_LowRes.pdf."},{"issue":"2","key":"1533_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/FTD.0000000000000266","volume":"38","author":"N Shuker","year":"2016","unstructured":"Shuker N, de Man FM, de Weerd AE, van Agteren M, Weimar W, Betjes MG, et al. Pretransplant tacrolimus dose requirements predict early posttransplant dose requirements in blood group AB0-incompatible kidney transplant recipients. Ther Drug Monit. 2016;38(2):217\u201322.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"1533_CR30","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/tri.14145","volume":"34","author":"AE de Weerd","year":"2021","unstructured":"de Weerd AE, van den Brand J, Bouwsma H, de Vries APJ, Dooper I, Sanders JF, et al. ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: a propensity-matched analysis. Transpl Int. 2021;34(12):2706\u201319.","journal-title":"Transpl Int"},{"issue":"5","key":"1533_CR31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/FTD.0b013e318296045b","volume":"35","author":"L Elens","year":"2013","unstructured":"Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35(5):608\u201316.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1533_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cpt.2220","volume":"110","author":"P Fontova","year":"2021","unstructured":"Fontova P, Colom H, Rigo-Bonnin R, Bestard O, Vidal-Alabr\u00f3 A, van Merendonk LN, et al. Sustained inhibition of calcineurin activity with a melt-dose once-daily tacrolimus formulation in renal transplant recipients. Clin Pharmacol Ther. 2021;110(1):238\u201347.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1533_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.78","volume":"3","author":"DJ Moes","year":"2014","unstructured":"Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometr Syst Pharmacol. 2014;3(2): e100.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"5","key":"1533_CR34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/pgs.10.43","volume":"11","author":"A Capron","year":"2010","unstructured":"Capron A, Mourad M, De Meyer M, De Pauw L, Eddour DC, Latinne D, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11(5):703\u201314.","journal-title":"Pharmacogenomics"},{"issue":"9","key":"1533_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/FPC.0000000000000296","volume":"27","author":"N Lloberas","year":"2017","unstructured":"Lloberas N, Elens L, Llaudo I, Padulles A, van Gelder T, Hesselink DA, et al. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenet Genom. 2017;27(9):313\u201322.","journal-title":"Pharmacogenet Genom"},{"issue":"8","key":"1533_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00228-022-03323-0","volume":"78","author":"MI Francke","year":"2022","unstructured":"Francke MI, Visser WJ, Severs D, de Mik-van Egmond AME, Hesselink DA, De Winter BCM. Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients. Eur J Clin Pharmacol. 2022;78(8):1273\u201387.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1533_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/tpj.2015.87","volume":"17","author":"K Sanghavi","year":"2017","unstructured":"Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, et al. Genotype-guided tacrolimus dosing in African\u2013American kidney transplant recipients. Pharmacogenomics J. 2017;17(1):61\u20138.","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"1533_CR38","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1111\/j.1600-6143.2012.04232.x","volume":"12","author":"PA Jacobson","year":"2012","unstructured":"Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12(12):3326\u201336.","journal-title":"Am J Transplant"},{"issue":"2","key":"1533_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67\u201376.","journal-title":"Drug Metab Rev"},{"issue":"6\u20137","key":"1533_CR40","first-page":"479","volume":"57","author":"S Fukatsu","year":"2001","unstructured":"Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6\u20137):479\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"1533_CR41","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/sj.bmt.1703224","volume":"28","author":"P Jacobson","year":"2001","unstructured":"Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant. 2001;28(8):753\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1533_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/00498254.2019.1607918","volume":"50","author":"L Chen","year":"2020","unstructured":"Chen L, Lu X, Tan G, Zhu L, Liu Y, Li M. Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients. Xenobiotica. 2020;50(2):186\u201391.","journal-title":"Xenobiotica"},{"issue":"3","key":"1533_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.krcp.2012.06.007","volume":"31","author":"SS Han","year":"2012","unstructured":"Han SS, Kim DH, Lee SM, Han NY, Oh JM, Ha J, Kim YS. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney Res Clin Pract. 2012;31(3):157\u201362.","journal-title":"Kidney Res Clin Pract."},{"issue":"3","key":"1533_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122399","volume":"10","author":"JR Lee","year":"2015","unstructured":"Lee JR, Muthukumar T, Dadhania D, Taur Y, Jenq RR, Toussaint NC, et al. Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS ONE. 2015;10(3): e0122399.","journal-title":"PLoS ONE"},{"issue":"3","key":"1533_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1124\/dmd.118.084772","volume":"47","author":"Y Guo","year":"2019","unstructured":"Guo Y, Crnkovic CM, Won KJ, Yang X, Lee JR, Orjala J, et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. Drug Metab Dispos. 2019;47(3):194\u2013202.","journal-title":"Drug Metab Dispos"},{"issue":"7762","key":"1533_CR46","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","volume":"570","author":"M Zimmermann","year":"2019","unstructured":"Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570(7762):462\u20137.","journal-title":"Nature"},{"issue":"1","key":"1533_CR47","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/FTD.0000000000001147","volume":"46","author":"A Abderahmene","year":"2024","unstructured":"Abderahmene A, Francke MI, Andrews LM, Hesselink DA, Amor D, Sahtout W, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus for tunisian adults after renal transplantation. Ther Drug Monit. 2024;46(1):57\u201366.","journal-title":"Ther Drug Monit"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01533-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01533-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:12:53Z","timestamp":1757466773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01533-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1533"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01533-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"18 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was obtained for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"D.A. Hesselink has received grant support (paid to his institution) from Astellas Pharma, Chiesi Farmaceutici SpA, and Bristol Myers-Squibb, as well as lecture and consulting fees from Astellas Pharma, Chiesi Farmaceutici SpA, Novartis Pharma, and Vifor Pharma. Laure Elens has received lecture fees (paid to his institution) from Astellas Pharma and Chiesi Farmaceutici SpA. All other authors declared no competing interests for this work. Dirk Jan A.R. Moes is an Editorial Board member of Clinical Pharmacokinetics. Dirk Jan A.R. Moes was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Medical Ethical Review Board of the Erasmus MC provided a waiver for the Medical Research Involving Human Subjects Act for this study (Medical Ethical Review Board number MEC-2021-0621). The study was conducted according to the principles of the Declaration of Helsinki (7th revision, October 2013, approved by the 64th WMA General Assembly, Fortaleza, Brazil).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"In the Erasmus MC Center, the LUMC, the Bellvitge University Hospital, and St. Luc Hospital Brussels all patients included in this study previously gave written informed consent for the use of their clinical and demographic data for research purposes and the use of body material for genotyping [, , \u2013]. Study practices were performed after approval from the local medical ethical committees. Patients who were not included in previous studies, were asked to participate in an ongoing biobanking program of the division of nephrology and transplantation (MEC-2010-022) during the work-up for transplantation in the Erasmus MC.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participating centers gave consent for publication of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data is available on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The NONMEM control stream is included in Supplementary Data S3.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Francke wrote the manuscript, all authors contributed to the writing of the manuscript. Francke, Sassen, Hesselink, and de Winter designed the research. Francke, Sassen, Lloberas, Colom, Elens, Moudio, de Vries, Moes, van Schaik, Hesselink, and de Winter performed the research and collected data or analyzed patient samples. Francke, Sassen, and de Winter analyzed the data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}